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Background: High stability and disease-specific disarrangements suggest that microRNA molecules (miRNAs) present in body
fluids are ideally suited for diagnostic applications, including gastric cancer (GC). However, the actual source of circulating miRNA
biomarkers in GC has not been adequately evaluated, particularly in the Western populations that have some distinct
characteristics compared with Asian patients.
Methods: Twenty treatment-naive patients with GC along with 20 cancer-free controls were recruited. miRCURY LNA miRNA
microarrays were used for miRNA expression profiling in primary tumours and adjacent healthy mucosa. Differentially expressed
serum miRNAs were identified with a high throughput TaqMan OpenArray technology in tumour-draining veins of the portal
system, as well as peripheral blood of the patients and controls.
Results: Tissue profiling identified 108 sequences differentially expressed between primary tumours and adjacent mucosa (87
upregulated and 21 downregulated). Twenty miRNAs found in serum of GC patients showed expression levels higher than in
controls. However, only seven of these molecules were overexpressed in primary tumours (miR-130a, miR-331, miR-19a, miR-223,
miR-106a, miR-21, and miR-374). Moreover, expression of miR-331 and miR-21 was significantly higher in the peripheral circulation
compared to tumour-draining veins of the portal system.
Conclusions: The results indicate that the majority of potential serum miRNA biomarkers may originate from tissues other than the
primary tumour.
Gastric cancer (GC) is the third leading cause of cancer death and a
major public health care problem worldwide, including in Western
populations (Ferlay et al, 2015). There are only limited diagnostic
methods for early detection and no effective screening programs
outside some Asian countries (Veitch et al, 2015). Consequently,
most cases are diagnosed at an advanced stage when the prognosis
is dismal (Van Cutsem et al, 2016). Thus, there is an urgent search
for new, preferentially non-invasive, biomarkers to allow early
detection of GC.
High stability and resistance to sample storage handling
combined with tissue- and disease-specific disarrangements
suggest that small non-coding RNAs (miRNAs), about 22
nucleotides long, present in body fluids are ideally suited for
diagnostic applications (Cortez et al, 2011). Indeed, preliminary
experiments using comprehensive expression profiling showed that
serum miRNAs can serve as a potential source for biomarkers for
the detection of human malignancies (Chen et al, 2008; Mitchell
et al, 2008). Multiple subsequent clinical studies, including those
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carried out in patients with GC, suggested that the diagnostic
performance of blood miRNAs signatures could outperform most
previous serological markers. Nevertheless, despite intensive
research with various profiling platforms, there are many unsolved
questions addressing the origin and function of circulating
miRNAs in cancer (Pritchard et al, 2012a).
Circulating miRNAs are believed to be actively secreted (Kosaka
et al, 2010) or passively released from dead cancer cells and
circulate packaged with RNA-binding proteins (Turchinovich et al,
2011), lipoproteins (Vickers et al, 2011), and extracellular vesicles
(Arroyo et al, 2011). However, other sources of miRNAs
circulating in cancer patients are also plausible, including immune
and other blood cells (Pritchard et al, 2012b). Consequently, some
studies demonstrated that only a small subset of circulating
miRNAs has a tumour-specific origin (Wulfken et al, 2011). This
phenomenon may be even more complex in malignancies of the
alimentary system, as experimental studies suggested the impor-
tance of hepatic elimination of exogenously administered miRNAs
(Bala et al, 2015; Imai et al, 2015). Consequently, the actual source
of blood miRNA biomarkers in gastric cancer has not been
adequately evaluated and little is known about their distribution,
particularly in the Western populations.
To the best of our knowledge, this is the first study of
comprehensive miRNome profiling aimed at evaluating the origins
of serum microRNA biomarkers for GC. Herein, we first
systematically examined miRNA expression profiles of primary
gastric cancer and adjacent healthy tissues. Subsequently, serum
miRNAs were identified to evaluate whether potential biomarkers
found in peripheral blood corresponded to those identified in
tumour-draining veins of the portal system.
MATERIALS AND METHODS
Study design and participants. The study was planned as a
prospective, open label clinical trial. A total of 20 treatment-naive
patients with histologically verified advanced non-cardia adeno-
carcinoma of the stomach scheduled for gastrectomy at the First
Department of Surgery Jagiellonian University Medical College
from January to December 2015 were recruited. A group of 20
patients subject to upper gastrointestinal endoscopy for complaints
related to non-malignant conditions, mostly GERD and chole-
lithiasis, was selected as controls. Tumour typing and staging were
adapted to the recent guidelines (Bosman et al, 2010; Edge et al,
2011). The study was approved by the Bioethics Committee of
Jagiellonian University and all participants provided their written
informed consent upon recruitment.
Sample processing. All blood and tissue samples were collected
prior to starting any tumour-oriented treatment. Peripheral venous
blood (5ml) was collected into sterile BD Vacutainer tubes under
fasting conditions immediately before surgery and from the control
subjects. Another 5ml was drawn intraoperatively from the
gastroepiploic vein located in the vicinity of the tumour. After
being allowed to clot at room temperature for 60min, samples
were centrifuged at 2000 g for 10min at 4 1C. The serum was
removed and stored at  80 1C until analysis.
Pairs of primary tumours and corresponding normal gastric
mucosa were sampled from patients’ surgical specimens immedi-
ately after resection. The fresh specimens were collected into RNase
free polypropylene tubes filled with RNAlater stabilisation solution
(Qiagen, Valencia, CA, USA) and stored at  80 1C until RNA was
extracted. Some portions of the collected specimens were used for
routine histopathology to verify adequate cellularity of samples
corresponding to tumour tissue and normal gastric mucosa.
RNA extraction. Total tissue RNA was extracted using miRCURY
RNA Isolation Kits (Exiqon, Vedbæk, Denmark) according to the
manufacturer’s instructions. Prior to RNA extraction from serum
samples, tubes were thawed completely on ice and 50 ml of each
serum aliquot was spiked-in with 10 fmol synthetic C. elegans
microRNA (cel-miR-39) (Applied Biosystems, Foster City, CA,
USA). Serum RNA extraction for profiling experiments was carried
out with TaqMan miRNA ABC Purification Kits Human Panel A
and B (Applied Biosystems) containing superparamagnetic Dyna-
beads covalently bound to 754 anti-miRNA oligonucleotides
selected for downstream applications. RNA concentrations were
measured with NanoDrop (Thermo Fisher Scientific, Waltham,
MA, USA) and overall sample quality was determined by RNA
integrity number (RIN) using Agilent Bioanalyser (Agilent
Technologies, Palo Alto, CA, USA).
Tissue microRNA expression profiling. Total RNA (750 ng)
isolated from tumour and healthy mucosa samples was labelled
with Hy3 and Hy5 fluorescent labels, using the miRCURY LNA
microRNA Hi-Power Labelling Kit, Hy3/Hy5 (Exiqon) following
the manufacturer’s instructions. Spike-in controls were added to
evaluate the labelling reaction, hybridisation, and the performance
of the array experiment. The labelled RNA samples were
hybridised to the miRCURY LNA microRNA Array 7th Gen
(Exiqon) containing capture probes targeting all microRNAs of
human origin registered in the miRBASE 19.0. The hybridisation
was performed using a Tecan HS4800 hybridisation station (Tecan,
Salzburg, Austria) according to the manufacturer’s protocol. After
hybridisation, the microarray slides were scanned using the Agilent
G2565BA Microarray Scanner System (Agilent Technologies) and
analysed with the ImaGene 9 software (BioDiscovery, El Segundo,
CA, USA). The obtained signals were background corrected and
data normalisation was performed with the Lowess (Locally
Weighted Scatterplot Smoothing) algorithm. MicroRNAs with
intensities above the detection threshold in less than 20% of the
samples were removed from the final dataset used for the
expression analysis. Microarray data were deposited in a Gene
Expression Omnibus database (accession no. GSE93415).
Serum microRNA expression profiling. Serum miRNAs were
profiled by qRT–PCR using the TaqMan OpenArray assays
(Applied Biosystems). Briefly, 0.9–2.7 ng of isolated RNA was
reverse transcribed in a 7.5 ml reaction volume using the TaqMan
MicroRNA Reverse Transcription Kit and Megaplex RT Primers
Human Pools A (v2.1) and B (v3.0) according to the manufac-
turer’s protocol (Applied Biosystems). The resulting cDNA (2.5 ml)
was preamplified to increase the quantity of specific cDNA targets
with Megaplex PreAmp Primers, Human Pools A (v2.1) and B
(v3.0) and the TaqMan PreAmp Master Mix in a final volume of
25 ml (Applied Biosystems). The preamplified product was diluted
40 folds and mixed 1:1v/v with the TaqMan OpenArray Real-Time
PCR Master Mix. 5 ml aliquots of the mixture were dispensed on an
OpenArray 384-well sample plate. Subsequently, TaqMan Open-
Array Human MicroRNA Panels were loaded with the OpenArray
AccuFill System and the PCR reactions were carried out with an
OpenArray System (Applied Biosystems) following the manufac-
turer’s instructions. Values of Ct were processed and exported to
DataAssist Software (Applied Biosystems).
Quantitative RT–PCR validation of tissue and serum miRNA
profiling experiments. The expression of selected miRNAs was
verified by qRT–PCR using TaqMan MicroRNA Assays (Applied
Biosystems) according to the manufacturer’s instructions. Briefly,
total RNA (10 ng) was reverse transcribed in a 15 ml reaction
volume using miRNA-specific RT primers and reagents from the
TaqMan MicroRNA Reverse Transcription Kit. The resulting
cDNA was diluted 1:15 and assayed in 20 ml reaction volumes by
qPCR using the corresponding miRNA assay primers and TaqMan
Universal PCR Master Mix, No AmpErase UNG. The amplifica-
tion was performed in 96-well plates with a ViiA 7 real-time PCR
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instrument (Applied Biosystems) in accordance with the manu-
facturer’s protocols. Three technical replicates were performed for
each assay, and the obtained mean Ct values were exported for
statistical analysis.
Normalisation for qRT–PCR microRNA expression assays.
Since there is no consensus about an optimal reference for relative
microRNA expression using the qRT–PCR assays, various controls
were evaluated separately for serum and tissue samples. Three
normalisation strategies for serum were examined with the
NormFinder algorithm using most stably expressed miRNAs
(endogenous controls), the mean expression of all the genes
(global normalisation (Mestdagh et al, 2009)), and cel-miR-39
(exogenous control). Reference controls for tissues were evaluated
using only the two former methods without exogenous spike-ins.
Finally, the expression levels of miRNAs normalised to the most
stable references (DCt) were calculated by subtracting the reference
Ct values from the Ct values of the miRNA of interest (Livak and
Schmittgen, 2001).
Statistical analysis. The complete-linkage method and Euclidean
distances were used for cluster analysis of microarray data.
Comparative expression analysis was done in the software R/
Bioconductor using mainly the limma package and moderated
t-statistics (Huber et al, 2015). For OpenArray and qRT–PCR
experiments, miRNAs with 410% undetectable expression data
were excluded from the calculations; otherwise missing data were
replaced by mean values. miRNAs with Ct value 5 amplification
cycles lower than negative control and not exceeding 40 cycles were
included for further analysis. The Mann–Whitney U-test was used
to detect differences with regard to DCt values. Relative miRNA
expression levels between groups were calculated by using the
DDCt method (Livak and Schmittgen, 2001). All raw P-values were
adjusted for multiple testing by the Benjamini, Krieger, Yekutieli
correction (Benjamini et al, 2006). Statistical analysis was
performed using the IBM SPSS Statistics v.24 software package
(IBM Corporation, Armonk, NY, USA).
RESULTS
Demographic and clinical characteristics of the study subjects.
Clinical and demographic data of the selected population are
summarised in Table 1. No significant difference in age, gender or
comorbidities distribution was observed between patients and
controls (P-values 40.05). Figure 1 shows a workflow for the
subsequent analytical steps.
Identification of reference controls for serum and tissue
qRT–PCR normalisation. As expected, tissue and blood samples
showed distinct variability of miRNA expression patterns using the
NormFinder algorithm. Tissue experiments identified miR-191-5p
and miR-298 as the optimum reference controls (Supplementary
Figure S1). However, the most stable controls for serum samples
included the combination of cel-miR-39 spike-in and miR-191-5p.
Tissue microRNA of primary tumours and healthy gastric
mucosa. A total of 975 miRNAs were detected above background
levels in at least two tumour samples, including a subset of 108
sequences where the absolute value of the log fold change
compared to healthy mucosa was larger than 1 and the corrected
P value was less than 0.05 (87 upregulated and 21 downregulated
miRNAs; Supplementary Table S1). The heat map diagram shows
the result of a two-way hierarchical clustering of microRNAs and
samples using the complete-linkage method together with the
Euclidean distance measure (Figure 2). Table 2 lists the 10 most
significant miRNAs upregulated in tumour tissues and ranked by
Table 1. Clinicopathological details of patients
Gastric cancer
(n¼20)
Controls
(n¼20)
Age, median (range) 64 (34–81) 62 (32–78)
Female/male, n (%) 9 (45)/11 (55) 9 (45)/11 (55)
Comorbidities, n (%)
Circulatorya 14 (70) 12 (60)
Pulmonaryb 2 (10) 2 (10)
Diabetes mellitus 4 (20) 5 (25)
Location, n (%)
Upper third 2 (10)
Middle third 8 (40)
Distal third 5 (25)
Whole stomach 5 (25)
Differentiation
Well 2 (10)
Moderately 3 (15)
Poor 15 (75)
Lauren classification
Intestinal 4 (20)
Diffuse 9 (45)
Mixed 7 (35)
Stage
II 2 (10)
III 13 (65)
IV 5 (25)
aIschemic heart disease, arrhythmia, previous myocardial infarction, coronary artery disease.
bAsthma, chronic obstructive pulmonary disease.
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Figure 1. Workflow showing the analytical strategy for the identification of microRNAs.
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the relative fold change compared to healthy mucosa. Subse-
quently, arrays experiments for these 10 molecules were validated
using qRT–PCR and expression data were normalised to the
average of assays for miR-191-5p and miR-298. The results of
qRT–PCR assays showed the same tendency as those of microarray
experiments for all miRNAs tested, but fold-change values were
generally lower (Table 2).
Serum miRNAs in gastric cancer and controls. Among the 434
miRNAs initially identified by TaqMan OpenArray assays, 31
sequences showed at least a twofold change in serum of gastric
cancer patients compared to controls (all up-regulated;
Supplementary Table S2). However, the subsequent qRT–PCR
validation experiments for these 31 molecules showed that
expression of only 20 miRNAs maintained their significance after
correction for multiple comparisons with a fold change ranging
from 4 (miR-30c) to 230 (miR-518f) (Table 3). There were no
significant differences in these miRNAs in relation to the primary
tumour (T2–T3 vs T4) or distant metastases (M0 vs M1).
Portal and peripheral blood miRNAs. Paired serum samples
obtained from peripheral and gastroepiploic veins were evaluated to
determine whether miRNA biomarkers found in peripheral blood
corresponded to those identified in tumour-draining veins of the
portal system. Eight of the evaluated miRNAs showed significantly
increased levels in the peripheral circulation by TaqMan OpenArray
cards and these sequences were subsequently validated with
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Figure 2. Heat map and unsupervised hierarchical clustering based on the 50 most differentially expressed miRNAs between primary tumours
and adjacent healthy mucosa. The miRNA overexpression is in green, and lower miRNA expression is in red. Numbers correspond to paired
samples from individual patients with ‘H’ denoting healthy mucosa.
Table 2. Ten most upregulated miRNAs in gastric cancer
tissue when compared with normal gastric mucosa
Annotation microRNA array RT–PCR validation
fold change P-valuea fold change P-valuea
miR-199a-3p 4.6 0.002 3.6 0.001
miR-199a-5p 3.7 0.001 2.7 0.002
miR-223-3p 3.7 0.002 3.1 0.005
miR-125b-5p 3.7 0.002 2.6 0.004
miR-27a-3p 3.5 0.002 2.8 0.001
miR-196a-5p 3.5 0.001 2.7 0.001
miR-23b-3p 3.5 0.002 3.1 0.002
miR-21-5p 3.2 0.001 2.6 0.004
miR-23a-3p 3.2 0.001 2.6 0.003
miR-20a-5p 3.0 0.001 2.0 0.001
Abbreviations: miRNA¼microRNA; RT–PCR¼ reverse transcriptase PCR.
aBenjamini, Krieger, and Yekutieli correction for multiple testing.
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qRT–PCR assays (Table 4). Moreover, the up-regulated group
included miR-331 and miR-21, which were earlier identified as
potential biomarkers of gastric cancer comparing miRNA expression
in peripheral blood of patients and controls (Table 3).
Correlation of tissue and blood miRNAs. To correlate profiles of
tissue and circulating miRNAs, we compared expression levels of
primary tumours and healthy gastric mucosa with peripheral blood
of patients and healthy controls. Among 20 miRNAs upregulated
in the peripheral blood of cancer patients, only seven (Figure 3)
demonstrated higher levels in tumours compared to adjacent
normal mucosa (miR-130a, miR-331, miR-19a, miR-223, miR-
106a, miR-21, and miR-374).
DISCUSSION
Circulating miRNAs found in all body fluids may potentially serve as
clinically relevant biomarkers of human malignancies. Herein, it was
found that serum levels of miRNAs detected in tumour-draining veins
of the portal system poorly corresponded to molecules abundantly
expressed by primary tumours of gastric cancer. Moreover, some
potential biomarkers were significantly up-regulated in peripheral
blood suggesting that these miRNAs are not released from the tumour.
The remarkable stability of miRNAs under various environmental
conditions initiated extensive research to validate serum and plasma
profiling in search of putative cancer biomarkers (Cortez et al, 2011).
Such attempts were undertaken also for gastric cancer, suggesting that
assays using blood miRNAs could markedly outperform currently
available solutions (Zhu et al, 2014a; Zhou et al, 2015). However, the
results of previous studies are highly inconsistent for most
malignancies and question any physiological role of miRNAs. One
of the potential explanations for this discrepancy is the suspicion that
potential biomarker candidates in fact originate from other sources
than the primary tumour, such as normal tissues of other organs or
blood cells (Pigati et al, 2010; Ribeiro-dos-Santos et al, 2010).
Comprehensive expression profiling of miRNAs in the current
study based on a well-defined population of Western patients with
Table 3. Upregulated serum miRNAs evaluated by qRT–PCR in the peripheral blood of patients with gastric cancer when
compared with healthy controls
miRNAs DCthealthy DCtcancer DDCt 2
–DDCt Corrected Pa
miR-518f  4.50±10.78  12.35±1.99  7.85 230.67 0.017
miR-130a 10.96±3.48 6.62±3.42  4.34 20.22 0.017
miR-212 8.81±2.36 4.58±2.65  4.22 18.70 0.007
miR-220 7.85±2.51 3.85±2.81  4.00 15.98 0.017
miR-433 9.03±1.67 5.19±3.15  3.84 14.29 0.025
miR-518d 8.77±3.76 5.43±3.24  3.35 10.18 0.037
miR-331 6.54±2.61 3.31±3.34  3.23 9.40 0.039
miR-19a 8.39±4.07 5.18±3.55  3.21 9.23 0.042
miR-365 10.66±3.22 7.62±3.12  3.04 8.25 0.037
miR-374 8.48±3.24 5.55±2.94  2.93 7.62 0.037
miR-296 7.74±4.29 4.86±3.14  2.88 7.37 0.039
miR-323-3p 9.21±1.60 6.59±2.94  2.63 6.18 0.046
miR-21 4.05±2.33 1.73±2.45  2.33 5.02 0.017
miR-146b 6.95±2.34 4.64±2.21  2.31 4.97 0.037
miR-146a 5.99±2.19 3.68±2.65  2.31 4.96 0.025
miR-106a 4.30±2.77 2.10±2.51  2.19 4.57 0.025
miR-223  2.65±2.32  4.78±2.57  2.12 4.35 0.025
miR-19b 2.45±2.23 0.36±2.63  2.09 4.26 0.025
miR-451 0.68±2.31  1.41±2.84  2.08 4.23 0.037
miR-30c 4.95±3.3 2.90±2.65  2.05 4.14 0.037
Abbreviations: miRNA¼microRNA; qRT–PCR¼quantitative reverse transcriptase PCR. Values are expressed as means±s.d. DCt¼Ct sampleCt average expression of cel-miR-39 and miR-191-5p.
DDCt¼DCt cancerDCt healthy.
aBenjamini, Krieger, and Yekutieli correction for multiple testing.
Table 4. Dysregulated miRNAs in peripheral circulation when compared with portal blood by qRT–PCR
miRNAs DCtperipheraL DCtportal DDCt 2
–DDCt P-value Corrected P-valuea
miR-21 1.73±2.45 5.28±3.09  3.55 11.71 0.001 0.004
miR-16 0.36±3.42 3.81±3.91  3.45 10.94 0.045 0.045
miR-99a 1.13±2.37 4.29±1.18  3.15 8.88 0.016 0.032
miR-95 6.96±2.71 10.04±2.21  3.08 8.46 0.012 0.032
miR-532 5.42±1.22 8.48±1.21  3.06 8.34 0.029 0.033
miR-891a 2.77±1.79 5.80±1.66  3.03 8.19 0.001 0.004
miR-331 3.31±3.34 5.40±2.37  2.09 4.26 0.028 0.033
miR-92a 0.19±1.89 2.26±2.02  2.07 4.20 0.027 0.033
Abbreviations: miRNA¼microRNA; qRT–PCR¼quantitative reverse transcriptase PCR. Values are expressed as means±s.d. DCt¼Ct sampleCt average expression of cel-miR-39 and miR-191-5p
DDCt¼DCt peripheralDCt portal.
aBenjamini, Krieger, and Yekutieli correction for multiple testing.
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gastric cancer provides a unique opportunity to study the origins of
potential serum biomarkers. Initially, 20 of 434 miRNA sequences
identified in peripheral blood serum were significantly up-
regulated in cancer patients. However, only seven of them showed
higher levels in primary tumours compared to adjacent normal
mucosa. Moreover, two potential biomarkers (miR-331 and miR-
21) demonstrated higher expression in peripheral blood than in the
tumour-draining vein. Altogether, our results strongly suggest non-
tumour origins for the majority of circulating miRNA biomarkers.
To our knowledge no previous study has evaluated the correlation
between potential miRNA biomarkers of gastric cancer in tumour
tissue with reference to portal and peripheral blood.
Early experiments have demonstrated that miRNAs originating
from human cancer xenografts enter the circulation and can be
readily measured in plasma (Mitchell et al, 2008). However, in the
mice model of gastric cancer, the comparison of tissue and serum
samples showed that only some miRNAs differentiating cancer and
normal tissues were overexpressed in serum (Rotkrua et al, 2013).
Human observations supporting such animal data are scarce as
even though some human studies correlated tissue and serum/
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Figure 3. Box plots of relative miRNA expression levels in tissues and peripheral blood. The statistical significance of differences was calculated
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Tissue and blood pools of gastric cancer microRNA BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.190 271
plasma levels of miRNAs, such assays were often carried out in
separate sets of patients and only a few reported results on a
within-patient basis. One such study examined levels of miRNAs
identified as significantly elevated (miR-223 and miR-21) and
decreased (miR-218) in plasma of gastric cancer compared to
healthy controls in 8 pairs of primary tumours and adjacent
normal tissue (Li et al, 2012). The expression of miR-223 and miR-
21 was higher in seven and eight, respectively, of eight cancer
tissues than in controls, whereas miR-218 was lower in seven of
eight patients. A similar experimental procedure was carried out in
four pairs of primary tumours and healthy adjacent tissues with
miR-378 identified as significantly elevated (threefold) in serum of
cancer patients compared to controls (Liu et al, 2012). However,
contrary to the expectations, tissue levels of miR-378 were
significantly lower in primary tumours than in healthy tissues.
Another study examined miR-451 and miR-486 identified as
diagnostic biomarkers for gastric cancer based on pre- and post-
operative paired plasma samples (Konishi et al, 2012). Despite high
diagnostic sensitivity and specificity of 96% and 100%, respectively,
for detecting GC compared to healthy controls, the miR-451
expression was found to be significantly lower in primary tumours
than in surrounding normal tissues, while miR-486 expression was
comparable. Altogether, these results imply that the circulating
pool of miRNA biomarkers of gastric cancer originates not only
from the primary tumour but also may reflect a yet unknown
biological phenomenon elicited by the presence of cancer.
It is still poorly understood why miRNAs with a relatively
low expression in primary tumours are abundantly expressed in
plasma or serum of GC patients compared to healthy controls.
There are at least two likely explanations. First, previous
observations in some other malignancies, such as breast cancer,
showed that only a few differentially expressed miRNAs were
common to tumours and serum and the potential biomarkers were
selectively released to circulation (Chan et al, 2013; Zhu et al,
2014b). Second, circulating miRNAs might also originate from
non-tumour tissues. Such a mechanism could explain our
observations related to miR-21 and miR-331 that achieved
markedly higher expression levels in peripheral blood than in the
vein draining the primary tumour. The plausibility of this
phenomenon is further substantiated by experiments carried out
with animal models and clinical observations of breast cancer
where some of extracellular miRNA was derived from normal
epithelial cells (Pigati et al, 2010).
Aberrant expression of miR-21 was identified in tissue and
blood of various malignancies, suggesting its potential role as a
diagnostic and prognostic biomarker (Yin et al, 2015). This was
likely related to the oncogenic activity of miR-21 that can stimulate
proliferation, migration, and invasion of cancer cells, including
gastric cancer (Sekar et al, 2016). In the latter case, the molecule
has been demonstrated to modulate the expression of multiple
genes, such as epidermal growth factor receptor (EGFR),
phosphatase and tensin homologue (PTEN), programmed cell
death 4 (PDCD4), Fas ligand (FASLG), and reversion-inducing
cysteine-rich protein with kazal motifs (RECK). Contrary to miR-
21, miR-331 has been much less extensively studied. Therefore, the
actual function of the molecule is somehow unclear as previous
experiments suggested its ability to promote proliferation and
metastasis (Chang et al, 2014), as well as inhibit cell growth and
promote apoptosis (Zhao et al, 2016). Nevertheless, it was reported
as a circulating biomarker for several tumours, including
hepatocellular carcinoma (Chen et al, 2015), laryngeal cancer
(Ayaz et al, 2013), and colorectal adenomas (Kanaan et al, 2013).
In the current study, the exact significance of increased expression
levels for miR-21 and miR-331 found in peripheral blood
compared to tumour-draining veins is unclear, but suggests that
some diagnostic miRNA biomarkers may actually originate from
tissues distant to the primary tumour.
Despite a moderate sample size, our results provide an important
framework for further studies focused on blood miRNome of
gastrointestinal malignancies to elucidate the origins of cancer-
associated biomarker miRNAs. However, some important limitations
should be considered. First, an appropriate normalisation strategy is a
key step for the accurate relative quantification of miRNA expression
levels with qRT–PCR. However, there are no generally accepted
internal controls for plasma/serum miRNA measurement to date,
and the discussion over selection of the most appropriate reference
genes in miRNA profiling studies is ongoing (Mestdagh et al, 2009;
Kok et al, 2015). To minimise the potential bias of using inadequate
controls we have tested all currently recommended normalisation
strategies (endogenous and exogenous controls, global normalisation)
and accordingly selected the most suitable approach. Second, we have
evaluated only serum miRNome without molecules present in
plasma or bound to membrane vesicles. Although some minor
differences in plasma and serum pools of miRNAs have been
demonstrated, they seem unlikely to affect identification of potential
biomarkers. Moreover, the selection of serum could be more relevant
for clinical applications. Third, no laser microdissection was used to
selectively isolate cancer cells for subsequent miRNA profiling, but
microscopic validation was used to confirm representative compo-
nents of primary tumours. Although the former method is more
specific for isolation of cancer cells, the latter more likely reflects the
heterogeneity of cellular components of the primary tumours and
their miRNA contents. Finally, differences in miRNA expression
patents within the primary tumour that were not evaluated in the
present study could potentially affect our results.
In summary, we conducted a comprehensive miRNA profiling of
primary gastric cancer and adjacent healthy tissues combined with
serum samples of portal and peripheral blood to investigate the
potential diagnostic biomarkers. Poor correlations between differen-
tially expressed miRNAs in tissues and blood suggest that a marked
proportion of potential biomarker molecules originate from tissues
other than the primary tumour, reflecting a yet unknown biological
phenomenon. This has important implications for further studies to
elucidate the role and origins of circulating cancer-associated miRNAs,
and should be validated by other research groups.
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